#Serplulimab

[hongkongdengyue]

Serplulimab

Serplulimab (Hans) Instructions

[Drug Name]

Generic Name: Serplulimab Injection

Trade Name: Hans

English Name: Serplulimab Injection

[Drug Ingredients]

Active Ingredient: Serplulimab (recombinant anti-programmed death receptor 1 humanized monoclonal antibody made from Chinese hamster ovary cells by DNA recombination technology).

Excipients: citric acid, sodium citrate, sodium chloride, mannitol, polysorbate 80 and water for injection.

[Drug Properties]

This product is a clear to opalescent, colorless or light brown liquid.

[Indications]

It is suitable for adult patients with advanced solid tumors with unresectable or metastatic microsatellite high instability (MSI-H).

. Patients with advanced colorectal cancer who have experienced disease progression after previous treatment with fluorouracil, oxaliplatin and irinotecan;

. Patients with advanced gastric cancer who have experienced disease progression after at least two lines of treatment and have no satisfactory alternative treatment options;

. Patients with other advanced solid tumors who have experienced disease progression after at least one line of treatment and have no satisfactory alternative treatment options.

[Drug specifications]

100 mg (10 ml)/bottle.

[Usage and Dosage]

This product must be used under the guidance of a physician with experience in tumor treatment.

Before using this product for treatment, the status of MSI-H must first be clarified. A fully validated test method should be used to confirm the presence of MSI-H before this product can be used for treatment.

Recommended dose:

The recommended dose of this product is 3 mg/kg, intravenous infusion once every 2 weeks until disease progression or intolerable toxicity occurs.

Atypical reactions have been observed in tumors treated with this product (for example, temporary enlargement of the tumor or the appearance of new small lesions in the first few months of treatment, followed by tumor shrinkage). If the patient's clinical symptoms are stable or continue to improve, even if there is preliminary evidence of disease progression, based on the judgment of overall clinical benefit, continued treatment with this product can be considered until disease progression is confirmed.